Warby Parker shows strong price momentum with a technical breakout above all major moving averages and rising volume accumulation, but the stock has already reached its analyst target with negative remaining upside, high short interest of 14%, and a below-average overall score of 4.5 limiting conviction.
Thesis pillars
- Strong Breakout Momentum→Stable
- Excellent Cash Conversion→Stable
- Target Reached Negative Asymmetry→Stable
- +1 more pillar — see the Why tab for full reasoning
Warby Parker Inc. (WRBY) Stock Analysis
Breakout setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $27.74 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.1/10.
Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323 U.S. retail stores and digital commerce, with frames starting at $95. Contact lenses contributed 11.1% and eye exams 6.4% of 2025 net revenue; the company... Read more
Sell if holding. Analyst target reached at $27.74 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.1/10. Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Score 4.1/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 32d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Warby Parker Inc.
About Warby Parker Inc.
Warby Parker operated 323 U.S. retail stores at December 31, 2025, selling eyeglasses, contact lenses (11.1% of 2025 net revenue), and eye exams and vision care (6.4% of 2025 net revenue), with all eyewear regulated by the U.S. FDA as a medical device. The company employed 4,036 people and sold frames starting at $95 in a U.S. eyewear market the Vision Council estimated at $70 billion as of December 2025. Insurance-backed purchases were only 8.3% of 2025 revenue despite insurance covering roughly 60% of industry-wide U.S. vision care purchases.
Warby Parker generates revenue through direct-to-consumer sales of prescription eyewear, contacts, and eye care services across 323 stores and its e-commerce platform. The company designs eyewear in-house at its New York City headquarters and manufactures through a network of more than 30 partners spanning frame factories, lens suppliers, and distribution centers across China, Japan, Vietnam, Italy, and Thailand, with in-house optical labs in Sloatsburg, New York, and Las Vegas, Nevada. The filing flags dependence on a limited number of frame and lens suppliers and reliance on Amazon Web Services for technology infrastructure. Competing against vertically integrated players EssilorLuxottica and VSP (which own frame brands, lens networks, and vision insurance plans) as well as low-priced online rival Zenni Optical, Warby Parker remains underpenetrated in insurance-backed purchases relative to the broader category. Progressive lenses represented 22.3% of prescription units at December 31, 2025, compared with approximately 40% industry-wide, indicating an underpenetrated premium-lens category.
Show full overview
Warby Parker sources frames and lenses from a network of more than 30 manufacturing partners located most notably in China, Japan, Vietnam, Italy, and Thailand, with the Risk Factors Summary explicitly flagging dependence on a limited number of suppliers and contract manufacturers. A loss of any of these partners could negatively affect the business, per the filing. The company also relies on Amazon Web Services for its entire technology infrastructure; the 10-K states that any disruption of or interference with that service could adversely affect business, financial condition, or operations — a single-platform dependency without a named alternative cloud provider.
See also: Healthcare · Medical Instruments & Supplies
From Warby Parker Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-07-07Recent Developments — Warby Parker Inc.
Latest news
- NEWS Reflecting On Beauty and Cosmetics Retailer Stocks’ Q4 Earnings: Warby Parker (NYSE:WRBY) - StockStory — StockStory neutral
- NEWS Warby Parker (WRBY) Q1 earnings report preview: What to look for - MSN — MSN neutral
- NEWS Warby Parker (WRBY) Q1 Earnings Report Preview: What To Look For - StockStory — StockStory neutral
- NEWS Reflecting on beauty and cosmetics retailer stocks’ Q4 earnings: Warby Parker (NYSE:WRBY) - MSN — MSN neutral
- NEWS How Warby Parker (WRBY) prepares for market disruptions | Q4 2025: Earnings Underperform - Revenue Report - Newser — Newser negative
Generated 2026-07-07T15:22:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierlimited number of suppliers10-K Item 1A: 'We face risks associated with suppliers from whom our products are sourced and are dependent on a limited number of suppliers.'
- MEDIUMSupplierAmazon Web Services10-K Item 1A: 'Our business relies on Amazon Web Services'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $27.74 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Weak overall score: 4.1/10. Chart setup: Golden cross, above all MAs, RSI 55, MACD bullish. Prior stop was $25.83. Score 4.1/10, moderate confidence.
Take-profit target: $30.27 (+9.0% upside). Prior stop was $25.83. Stop-loss: $25.83.
Analyst target reached - limited upside remaining; Weak overall score: 4.1/10; Weak growth.
Warby Parker Inc. trades at a P/E of 2926.0 (forward 44.2). TrendMatrix value score: 5.0/10. Verdict: Sell.
21 analysts cover WRBY with a consensus score of 4.0/5. Average price target: $30.
What does Warby Parker Inc. do?Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323...
Warby Parker designs and sells prescription eyeglasses, sunglasses, contact lenses, and eye care services through 323 U.S. retail stores and digital commerce, with frames starting at $95. Contact lenses contributed 11.1% and eye exams 6.4% of 2025 net revenue; the company competes against EssilorLuxottica and VSP in a U.S. eyewear market estimated at $70 billion.